LPCN - Cantor initiates Lipocine with an overweight rating sees 121% upside

syahrir maulana/iStock via Getty Images Cantor Fitzgerald has initiated shares of Lipocine (LPCN) with an overweight rating and a $3 price target (~121% upside). The firm says the company has "multiple shots on goal across its metabolic and endocrine disorders pipeline over the next 12-18 months." Cantor believes the company's pipeline, which includes TLANDO, LPCN 1144, LPCN 1148, LPCN 1107, and LPCN 1154 are underappreciated. In addition, they expect upwards earning estimate revisions. Lipocine shares are up 1.8% to $1.39 in morning trading.

For further details see:

Cantor initiates Lipocine with an overweight rating, sees 121% upside